RYTM - Rhythm Pharmaceuticals Inc.
IEX Last Trade
47.39
1.290 2.722%
Share volume: 247,081
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$46.10
1.29
2.80%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-03 | 2022-11-08 | 2023-03-01 | 2023-05-02 | 2023-08-01 | 2023-11-08 | 2024-02-29 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 277.675 M | 389.614 M | 382.481 M | 345.678 M | 309.943 M | 354.199 M | 332.745 M | 258.651 M | |
| Current Assets | 249.332 M | 361.874 M | 354.236 M | 317.838 M | 283.878 M | 329.201 M | 308.268 M | 235.753 M | |
| Inventories | 0.000 | 0.000 | 2.917 M | 5.487 M | 6.178 M | 7.762 M | 8.624 M | 8.507 M | |
| Other Current Assets | 12.029 M | 10.751 M | 11.807 M | 9.652 M | 10.267 M | 7.638 M | 8.931 M | 11.352 M | |
| Short Term Investments | 12.029 M | 10.751 M | 11.807 M | 9.652 M | 10.267 M | 7.638 M | 8.931 M | 11.352 M | |
| Total Receivables | 1.707 M | 3.328 M | 6.224 M | 8.117 M | 13.831 M | 14.541 M | 14.867 M | 14.695 M | |
| Current Cash | 235.596 M | 347.795 M | 333.288 M | 294.582 M | 253.602 M | 299.260 M | 275.846 M | 201.199 M | |
| Total Non-current Assets | 28.343 M | 27.740 M | 28.245 M | 27.840 M | 26.065 M | 24.998 M | 24.477 M | 22.898 M | |
| Property Plant Equipment | 2.559 M | 2.426 M | 2.197 M | 2.001 M | 1.773 M | 1.545 M | 1.341 M | 1.149 M | |
| Other Assets | 17.145 M | 16.889 M | 17.837 M | 17.842 M | 16.508 M | 15.883 M | 15.780 M | 14.474 M | |
| Intangible Assets | 8.311 M | 8.097 M | 7.883 M | 7.669 M | 7.456 M | 7.242 M | 7.028 M | 6.815 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 277.675 M | 389.614 M | 382.481 M | 345.678 M | 309.943 M | 354.199 M | 332.745 M | 258.651 M | |
| Total liabilities | 82.047 M | 108.419 M | 118.219 M | 125.915 M | 127.658 M | 156.725 M | 162.986 M | 197.070 M | |
| Total current liabilities | 44.570 M | 33.098 M | 39.809 M | 46.029 M | 46.103 M | 50.144 M | 55.203 M | 54.160 M | |
| Accounts Payable | 6.012 M | 4.933 M | 4.797 M | 13.347 M | 8.383 M | 3.839 M | 4.885 M | 7.550 M | |
| Other liabilities | 1.590 M | 920.000 K | 1.340 M | 1.290 M | 1.320 M | 1.190 M | 1.150 M | 35.258 M | |
| Current long term debt | 644.000 K | 664.000 K | 684.000 K | 705.000 K | 726.000 K | 748.000 K | 770.000 K | 793.000 K | |
| Long term debt | 35.887 M | 74.401 M | 77.070 M | 78.596 M | 80.235 M | 105.391 M | 106.633 M | 107.652 M | |
| Other liabilities | 1.590 M | 920.000 K | 1.340 M | 1.290 M | 1.320 M | 1.190 M | 1.150 M | 35.258 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 195.628 M | 281.195 M | 264.262 M | 219.763 M | 182.285 M | 197.474 M | 169.759 M | 61.581 M | |
| Common stock | 50.398 M | 51.401 M | 56.357 M | 56.709 M | 56.868 M | 57.875 M | 59.241 M | 60.144 M | |
| Retained earnings | -626.704 M | -667.565 M | -710.058 M | -762.237 M | -808.940 M | -853.103 M | -894.736 M | -1.036 B |